Werewolf Therapeutics Adopts New Bylaws and Elects Directors

An update from Werewolf Therapeutics ( (HOWL) ) is now available.

On June 12, 2025, Werewolf Therapeutics, Inc. adopted new bylaws to clarify procedural mechanics for stockholder nominations and proposals, specify meeting presiders, and make administrative updates. During the same annual meeting, stockholders elected three directors for three-year terms and ratified Ernst & Young LLP as the independent accounting firm for 2025.

The most recent analyst rating on (HOWL) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.

Spark’s Take on HOWL Stock

According to Spark, TipRanks’ AI Analyst, HOWL is a Neutral.

Werewolf Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. While technical analysis suggests some short-term momentum, valuation concerns and the risk of delisting due to the Nasdaq deficiency notice weigh on the score. However, progress in clinical trials and optimistic analyst ratings offer potential future upside, though they have yet to materially improve the company’s financial position.

To see Spark’s full report on HOWL stock, click here.

More about Werewolf Therapeutics

Werewolf Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies.

Average Trading Volume: 430,530

Technical Sentiment Signal: Hold

Current Market Cap: $55.19M

For an in-depth examination of HOWL stock, go to TipRanks’ Overview page.